Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design

Documents similaires

• Can the Development of Orphan Drugs Include Wider Patient Engagement? A Citizens' Jury to Explore a Promissory Notion
  par: Julia Frost, et autres
  Publié: (2025)
• Public and Patient Involvement and Engagement in Clinical Trials: A Multi‐Perspective Mixed‐Methods Evaluation of the ROWTATE Programme
  par: Blerina Kellezi, et autres
  Publié: (2026)
• Evaluating Patient and Public Involvement and Engagement Activity Within the 3DPiPPIn Trial: A Qualitative Exploration of Contributors' Perspectives on Their Impact
  par: Ime Umoabasi, et autres
  Publié: (2026)
• Can a Public and Patient Involvement (PPI) Informed Participant Information Leaflet (PIL) Improve Trial Recruitment, Retention, and Quality of Decision Making? Results of a Randomised Controlled Double‐Blind Study Within a Trial (SWAT)
  par: Linda O'Neill, et autres
  Publié: (2025)
• Understanding Barriers and Facilitators for Ethnic Minority Groups to Audio Recording Recruitment Discussions in Clinical Trials: A Participatory Approach to Improving Informed Consent and Participation
  par: Saba Faisal, et autres
  Publié: (2025)